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Abstract
Background: Aboriginal and Torres Strait Islander peoples in Australia have been found to have poorer cancer
survival than non-Aboriginal people. However, use of conventional relative survival analyses is limited due to a lack
of life tables. This cohort study examined whether poorer survival persist after accounting for competing risks of
death from other causes and disparities in cancer stage at diagnosis, for all cancers collectively and by cancer site.
Methods: People diagnosed in 2000–2008 were extracted from the population-based New South Wales Cancer
Registry. Aboriginal status was multiply imputed for people with missing information (12.9%). Logistic regression
models were used to compute odds ratios (ORs) with 95% confidence intervals (CIs) for ‘advanced stage’ at
diagnosis (separately for distant and distant/regional stage). Survival was examined using competing risk regression
to compute subhazard ratios (SHRs) with 95%CIs.
Results: Of the 301,356 cases, 2517 (0.84%) identified as Aboriginal (0.94% after imputation). After adjusting for age,
sex, year of diagnosis, socio-economic status, remoteness, and cancer site Aboriginal peoples were more likely to
be diagnosed with distant (OR 1.30, 95%CI 1.17–1.44) or distant/regional stage (OR 1.29, 95%CI 1.18–1.40) for all
cancers collectively. This applied to cancers of the female breast, uterus, prostate, kidney, others (those not included
in other categories) and cervix (when analyses were restricted to cases with known stages/known Aboriginal status).
Aboriginal peoples had a higher hazard of death than non-Aboriginal people after accounting for competing risks
from other causes of death, socio-demographic factors, stage and cancer site (SHR 1.40, 95%CI 1.31–1.50 for all
cancers collectively). Consistent results applied to colorectal, lung, breast, prostate and other cancers.
Conclusions: Aboriginal peoples with cancer have an elevated hazard of cancer death compared with non-
Aboriginal people, after accounting for more advanced stage and competing causes of death. Further research is
needed to determine reasons, including any contribution of co-morbidity, lifestyle factors and differentials in service
access to help explain disparities.
Keywords: Neoplasms, Staging, Indigenous, Survival analysis, Australia, Epidemiology
* Correspondence: hanna.tervonen@unisa.edu.au
1School of Health Sciences, Centre for Population Health Research, University
of South Australia, GPO Box 2471, Adelaide, SA 5001, Australia
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Tervonen et al. BMC Cancer  (2017) 17:398 
DOI 10.1186/s12885-017-3374-6
Background
Despite generally high standards of health care in
Australia, health inequalities exist by socio-economic
status, residential remoteness, migrant status and in par-
ticular, Aboriginal status [1]. Australian Aboriginal and
Torres Strait Islander peoples (referred to in this article
as Aboriginal peoples) experience mortality at a younger
age and higher health morbidity compared with non-
Aboriginal people [2, 3]. This disadvantage applies also
to cancer, although the available evidence is limited by
the incomplete recording of Aboriginal status on the
data sources used by cancer registries, which may par-
tially explain the reported lower cancer incidence among
Aboriginal peoples [4]. Several studies have shown that
Aboriginal peoples with cancer have lower survival com-
pared with non-Aboriginal people [4–15] although the
use of conventional relative survival analyses has been
limited due to a lack of life tables. Cancer survival
appeared to substantially improve for non-Aboriginal
people in Australia in 1991–2005, but less so for Abori-
ginal peoples, which has widened the survival gap [8].
Probable reasons for differences in cancer survival
include Aboriginal peoples being more likely to live in
remote areas, having poorer access to screening and
treatment services, receiving less optimal treatment and
having higher levels of comorbidities [7, 10, 16]. In
addition, available data indicate that Aboriginal peoples
have a higher incidence of cancers with a poorer prog-
nosis, reflecting differences in risk factor prevalence
[17, 18]. Compared with non-Aboriginal people, Abori-
ginal peoples were more likely to be diagnosed with
advanced stages for head and neck cancers [19], colon/
rectum, breast, and cervix cancers, and non-Hodgkin
lymphoma but not lung cancer [20]. Some studies have
found lower survival among Aboriginal than non-
Aboriginal people, even after adjustment for stage [4, 6,
9, 20], whereas other studies have indicated that the
survival gap narrowed and became non-significant after
adjustment for stage and other clinical factors [16] or
after adjustment for comorbidities, socioeconomic dis-
advantage and remoteness [5]. The causes of survival
disparities are complex, potentially geographically vari-
able, and not fully understood. The possible effect of
competing causes of death on survival estimates has
not been investigated directly.
New South Wales (NSW) has the largest Aboriginal
population in Australia, accounting for 30% of all Abori-
ginal peoples (overall 208,500 Aboriginal peoples lived in
NSW in 2011) [21]. Previous studies from NSW have
indicated that Aboriginal peoples have lower cancer sur-
vival than non-Aboriginal people (5-year survival 52.6%
and 65.4% respectively for cases diagnosed in 1999–
2007) [22]. A larger proportion of Aboriginal peoples
were found to be diagnosed with distant stage than for
non-Aboriginal people (19.3% vs. 13.5% for males; 19.2%
vs. 14.5% for females). The NSW Cancer Registry (NSW
CR) is the only Australian cancer registry routinely col-
lecting stage (extent of disease) at diagnosis for all solid
malignant tumours [23]. These data enable the simultan-
eous examination of differences in stage at diagnosis and
survival.
After adjustment for stage, previous studies have
reported lower survival for Aboriginal than non-
Aboriginal people for cancers of the breast, prostate,
lung, cervix, head and neck, stomach, pancreas and
non-Hodgkin lymphoma [4, 5, 7, 9, 24] and conflicting
results for colorectal cancer [9, 25]. Previous studies
have generally examined either survival from all causes
or disease-specific survival rather than using conven-
tional relative survival due to the absence of credible
life tables. Use of disease-specific mortality may be
vulnerable to censoring bias and all cause survival
masks the outcomes for cancer per se. To our know-
ledge, relative survival has only been used by Condon
et al. (2014) for a period of 2001–2005 [8]. This study
concluded that results from cause-specific and relative
survival models were largely similar for all sites but
there were differences in site-specific analyses. Our
study takes a different approach by analysing mortality
due to cancer taking competing causes into account.
This is important because there is evidence that Abori-
ginal peoples with cancer are more likely to die from a
non-cancer death than non-Aboriginal people [16].
The aim of this study was to examine whether poorer
survival persists after accounting for competing risks of
death from other causes and disparities in cancer stage
at diagnosis, for all cancers collectively and by cancer
site. We also report on the scale of disadvantage in can-
cer stage and survival experienced by Aboriginal peoples
in the context of inequalities experienced by other popu-
lation groups classified by socioeconomic status and
remoteness of residence.
Methods
Study design and data sources
This cohort study used population-based data from the
New South Wales Cancer Registry (NSW CR). The
NSW CR receives legally mandated reports of all cases
of primary invasive cancer (except non-melanoma skin
cancers) diagnosed in NSW residents. The NSW CR is a
case-based registry in which notifications relating to a
particular cancer are linked to a single person. If the
same person has another cancer, that cancer counts as a
second case. This study included cases diagnosed be-
tween January 2000, the point at which Aboriginal status
is regarded to have been more accurately recorded in
NSW, and December 2008 [26].
Tervonen et al. BMC Cancer  (2017) 17:398 Page 2 of 11
The NSW CR data include demographic information,
cancer diagnosis and death data, and residential address
at diagnosis. Death data were obtained through the
NSW Registry of Births, Deaths and Marriages and the
Australian Bureau of Statistics (ABS). Death data in-
cluded deaths due to cancer and deaths from other
causes.
Approval for the study was obtained from the NSW
Population and Health Services Research Ethics Com-
mittee (NSW PHSREC 2012 07410) and the Aboriginal
Health and Medical Research (AH&MRC) ethics com-
mittee. To undertake this study, the respective data
custodians for the NSW CR, the NSW Registry of
Births, Deaths and Marriages, and the ABS provided
approval to use each data set and to link records from
the NSW Cancer Registry to each data set. Input was
obtained from the NSW Cancer Institute’s Aboriginal
Advisory Group for data and linkage projects.
Measures
The main variable of interest was Aboriginal status
which was derived from multiple information sources,
including hospitals and the NSW Registry of Births,
Deaths and Marriages. For the purposes of this study,
and due to low numbers of Torres Strait Islander peo-
ples, Aboriginal and Torres Strait Islander peoples
were grouped together. Because of under-recording of
Aboriginal status in health and death registries, we
used multiple imputation (MI) to account for unknown
Aboriginal status [4].
Cancer primary site was classified according to the
International Classification of Diseases Oncology (ICD-
O-3) [27]. The following classifications were used in this
study: stomach (C16), colorectal (C18,C19-C21; separ-
ately also colon C18 and rectum C19-C21), liver (C22),
pancreas (C25), lung (C33,C34), cutaneous melanoma
(C44 with M872-M879), breast (C50), cervix (C53),
uterus (C54,C55), prostate (C61), kidney (C64-C66,C68),
bladder (C67), ill-defined & unspecified site & other rare
cancers (C26,C39,C42,C48,C76,C80), and all other inva-
sive cancer sites collectively that were not included in
the specific categories. This grouping was used because
it included the most common cancers among Aboriginal
and non-Aboriginal people. Similar categorisation was
used for classifying causes of cancer deaths by primary
site. For non-cancer deaths, the NSW CR did not record
the underlying causes of deaths.
Age was measured in years at time of cancer diagnosis.
Age was categorised as 0–39, 40–49, 50–59, 60–64, 65–
69, 70–74, 75–79, 80–84 and 85+ years, and expressed
as a categorical variable in the analyses. Broader categor-
isation into <50, 50–69 and ≥70 years was used for age-
stratified analyses. Sensitivity analyses with different age
categorisations were conducted but results remained
largely unchanged (data not shown).
Residential remoteness was based on the Accessibil-
ity/Remoteness Index of Australia (ARIA+) [28]. ARIA
+ was based on measures of physical road distance
between populated localities and the nearest service
centres. Residential remoteness was categorised into
major cities (reference category), inner regional, outer
regional and remote/very remote areas.
Socio-economic status was estimated using the Index of
Relative Socio-Economic Disadvantage (IRSD) based on
residential data by ABS Statistical Local Areas at the time
of diagnosis [29]. IRSD is one of the Socio-Economic
Indexes for Areas (SEIFAs) created by the ABS. IRSD was
categorised into quintiles (1: least disadvantaged (refer-
ence category) to 5: most disadvantaged).
Stage (extent of disease) is defined as the highest de-
gree of spread based on all diagnostic and therapeutic
evidence obtained within four months of cancer first
being diagnosed according to international guidelines
widely used by cancer registries worldwide [23, 30].
Stage was categorised as localised, regional, distant or
unknown (if enough information to assign stage was
not available).
Statistical analyses
A MI model previously created by the NSW CR was
modified for the purposes of this study [4, 22]. Logistic
regression was used as a modelling approach to impute
the values for cases with unknown Aboriginal status
(n = 38,764, 12.9%). According to the missing at random
(MAR) assumption, the probability of missingness can
depend on the observed, but not on the missing data
[31]. Therefore, MI model must include all predictors
that are relevant to the missing-data mechanism [32].
Predictor variables included in the regression model
were 5-year age group, sex, country of birth, stage at
diagnosis, cancer site, one-year survival, Area Health
Service of residence at diagnosis, SEIFA quintile, re-
moteness, year of diagnosis, and percentage of the local
government area population identifying as Aboriginal.
Use of several covariates as predictors of missing Abo-
riginal status is likely to make the MAR assumption
tenable [4]. We imputed 20 datasets which were used
in the analyses. MI estimates of coefficients and stand-
ard errors adjusted for the variability between imputa-
tions were computed using Rubin’s combination rules
[33]. Cases with missing information with any of the
predictor variables were excluded (n = 39). Sensitivity
analyses excluding cases with missing Aboriginal status
were also conducted.
Initially the study population was described using fre-
quency distributions and cross-tabulations (both for
complete-case and imputed data). Bi-variable associations
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between Aboriginal and non-Aboriginal people in
complete-case data were explored using the Pearson chi-
square test and Mann-Whitney (Wilcoxon rank-sum) test.
Logistic regression models were used to examine asso-
ciations between Aboriginal status and stage of cancer at
diagnosis for all cancers collectively and by cancer site,
including cases with unknown stage. We also conducted
sensitivity analyses excluding cases with unknown stage.
Separate analyses were performed for distant and dis-
tant/regional stage, respectively, compared with other
stage categories as the outcome variable and the term
‘advanced stage’ was used when referring to these out-
comes. Multivariable models were fitted, adjusting for
age, sex, year of diagnosis, remoteness and SEIFA quin-
tile (model 1) and also cancer site (model 2). The effect
of adding an interaction term for Aboriginal status and
age to model 2 was examined using complete-case data.
Results were presented as odds ratios (ORs) with 95%
confidence intervals (CI).
Competing risk regression models using the Fine and
Gray method were used to examine hazard of death
due to cancer among Aboriginal compared with non-
Aboriginal people for all cancers collectively and by site
[34]. Competing risk regression models the subhazard
function of an event of interest in the presence of com-
peting events (also known as the cumulative incidence
function). Deaths due to causes other than the cancer
of diagnosis were regarded as competing events. Cases
were followed from the time of diagnosis to death or to
December 2008, which ever occurred first. Death
certificate only (DCO) cases or cases found at post-
mortem were excluded from survival analyses
(n = 4406, 1.5%; a similar proportion affecting both
Aboriginal and non-Aboriginal people, (Χ2[df=1] = 2.7,
p = 0.098). Multivariable models were adjusted for age,
sex, year of diagnosis, remoteness and SEIFA quintile
(model 1), stage (model 2) and cancer site (model 3).
The effect of adding an interaction term for Aboriginal
status and age to the final model was examined using
complete-case data. Results were presented as subha-
zard ratios (SHRs) with 95%CIs. Final models were
found to satisfy proportional hazards assumptions.
All analyses were performed using Stata Statistical
Software: Release 12 (College Station, TX: StataCorp LP,
2011). Stata stcrreg command was used in survival ana-
lysis [35] and Stata mi commands were used in multiple
imputation [32].
Results
Altogether 301,356 cases with invasive cancer were diag-
nosed between 2000 and 2008 and followed for a mean
duration of 2.8 years. Of these, 2517 (0.84%) were identi-
fied as Aboriginal and 38,764 (12.9%) had an unknown
Aboriginal status. Aboriginal peoples were generally
younger than non-Aboriginal people (median age 61 vs.
68 years) (Fig. 1). After imputation, the proportion of
Aboriginal peoples increased from 0.84% to 0.94%
(95%CI 0.90–0.98%) of all cases included into the ana-
lyses (compared to Aboriginal peoples accounting for
3.0% of Australia’s population). Characteristics of the
study population are shown in Table 1.
Stage at diagnosis
After adjustment for age, sex, remoteness, SEIFA and
diagnostic year, Aboriginal peoples were more likely to
be diagnosed with a distant stage compared with non-
Aboriginal people (OR 1.59, 95%CI 1.45–1.75) (model 1)
(Table 2). After further adjustment for site, the odds
ratio decreased to 1.30 (95% CI 1.17–1.44) (model 2).
Aboriginal status showed a stronger association with
distant stage than did remoteness or SEIFA (OR for
remote/very remote compared with major cities 1.02,
95%CI 0.89–1.16; OR for most compared with least
disadvantaged SEIFA quintile 1.40, 95%CI 1.35–1.45).
Results were similar when the outcome of interest was a
diagnosis with distant/regional stage.
In age-stratified analyses, the higher odds of being di-
agnosed with distant stage among Aboriginal compared
with non-Aboriginal people tended to be more pro-
nounced for people aged under 50 years (OR 1.51,
95%CI 1.20–1.91) compared with those aged 50–69 years
(OR 1.18, 95%CI 1.02–1.38) or 70+ years (OR 1.24,
95%CI 1.02–1.51). However, the interaction between
Aboriginal status and age was not statistically significant.
In cancer site-stratified analyses, an association be-
tween Aboriginal status and distant stage was observed
for female breast (OR 1.62, 95%CI 1.11–2.36), uterus
(OR 2.19, 95%CI 1.04–4.64), prostate (OR 2.59, 95%CI
1.65–4.08), kidney (OR 1.87, 95%CI 1.16–3.03) and other
cancers (OR 1.63, 95% CI 1.30–2.04) (Table 3). When
analysing distant/regional stage at diagnosis as the out-
come, associations for uterus and prostate cancers atten-
uated. In addition, elevated odds of advanced stage
among Aboriginal peoples were detected for colorectal
cancer when distant/regional stage was the outcome
(OR 1.34, 95%CI 1.05–1.70). Elevated odds were appar-
ent for rectum cancer (OR 1.82, 95%CI 1.21–2.73) but
not colon cancer.
Sensitivity analyses excluding cases with unknown
stage produced largely similar risk estimates for Aborigi-
nal status (data not shown), with the exception of a
stronger association between Aboriginal status and ad-
vanced stage for cervix cancer (distant stage OR 2.24,
95%CI 1.04–4.80; distant/regional stage OR 1.79, 95%CI
1.01–3.17 for Aboriginal compared with non-Aboriginal
people). Results were similar when those with missing
Aboriginal status were excluded from the analyses.
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Survival
Competing risk regression modelling, adjusted for age,
sex, year of diagnosis, remoteness and SEIFA, indicated
that Aboriginal peoples had an elevated hazard of death
from the cancer compared with non-Aboriginal people
(SHR 1.76, 95%CI 1.65–1.88) (Table 4). After further
adjustment for stage, the subhazard ratio decreased to
1.54 (95%CI 1.44–1.65) and then further to 1.40 (95%CI
1.31–1.50) after adjusting for cancer site.
An interaction term for Aboriginal status and age indi-
cated varying effects in different age groups. In age-
stratified analyses, Aboriginal peoples aged less than
50 years tended to have a higher elevated relative risk of
death from the cancer compared with non-Aboriginal
people (SHR 1.65, 95%CI 1.41–1.93) than those aged
50–69 (SHR 1.45, 95%CI 1.32–1.60) and 70+ years (SHR
1.15, 95%CI 1.02–1.29).
After adjustment for demographic factors and stage,
site-stratified analyses showed an elevated hazard of
death from the cancer for Aboriginal peoples for colo-
rectal (SHR 1.57, 95%CI 1.32–1.87), lung (SHR 1.39,
95%CI 1.24–1.56), breast (SHR 1.62, 95%CI 1.22–2.16),
prostate (SHR 1.86, 95%CI 1.24–2.77) and other cancers
(SHR 1.40, 95%CI 1.23–1.59) (Table 3).
Results remained similar when cases with unknown
Aboriginal status were excluded.
Discussion
This is one of the largest studies examining cancer stage
and stage-adjusted survival disparities among Aboriginal
and non-Aboriginal people in Australia, made possible
by routine recording of stage by the NSW CR. The main
finding of this study was that after accounting for
competing causes of death and more advanced stage,
Aboriginal peoples with cancer still had worse survival
than non-Aboriginal people. Our results also indicate
that Aboriginal status is a stronger predictor of advanced
stage and hazard of cancer death than living in remote
or socio-economically disadvantaged areas, as classified
in this study. Indigenous populations worldwide face
similar disparities which are shaped by historical process
of colonisation, marginalisation, dislocation, trauma and
the absence of recognition [36, 37]. Therefore, social de-
terminants, referring to historical, political, economic
and social contexts into which people are born, may be
especially important for health outcomes, including can-
cer outcomes, of Aboriginal peoples [38, 39].
Aboriginal peoples were more likely to be diagnosed
with an advanced stage compared with non-Aboriginal
people. Previous studies have similarly reported that
Aboriginal peoples had more advanced stage [4–6, 20]
but to our knowledge only one previous study in
addition to ours has systematically examined cancer site-
specific differences [19]. Age-stratified analyses indicated
that the association between Aboriginal status and
advanced stage tended to be stronger in younger age
groups, however, interaction was not statistically sig-
nificant. The reasons for this finding are not known, al-
though it may be explained by older peoples having
more contact with the health care system, and thus ex-
periencing more opportunities for clinical detection of
cancer, irrespective of Aboriginal status. Another possi-
bility is that older Aboriginal peoples may be more
health-conscious and more inclined to respond to
symptoms because they are a select group of people
who have already survived to that age. Reasons behind
Fig. 1 The age distributions at the time of diagnosis among non-Aboriginal and Aboriginal people
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Table 1 Characteristics of the study population overall and by Aboriginal status, NSW Cancer Registry 2000–2008




n (%) n (CC %) (MI %)b n (CC %) (MI %)b P valuec
Males 168,326 (55.9) 1313 (52.2) (52.0) 144,109 (55.4) (55.9) Χ2 (1) p = 0.001
Age at diagnosis Χ2 (8) p < 0.001;
MW(z) = 24.3,
p < 0.001
0–39 17,031 (5.7) 263 (10.5) (11.0) 13,398 (5.2) (5.6)
40–49 24,538 (8.1) 360 (14.3) (14.9) 19,810 (7.6) (8.1)
50–59 50,578 (16.8) 570 (22.7) (22.7) 42,361 (16.3) (16.7)
60–64 34,754 (11.5) 358 (14.2) (14.1) 29,730 (11.4) (11.5)
65–69 38,813 (12.9) 288 (11.4) (11.3) 33,548 (12.9) (12.9)
70–74 40,688 (13.5) 290 (11.5) (11.4) 35,587 (13.7) (13.5)
75–79 40,276 (13.4) 210 (8.3) (7.9) 35,701 (13.7) (13.4)
80–84 30,592 (10.2) 103 (4.1) (4.0) 27,658 (10.6) (10.2)
85+ 24,086 (8.0) 75 (3.0) (2.9) 22,282 (8.6) (8.0)
Residential remoteness Χ2 (3) p < 0.001;
MW(z) = −30.3,
p < 0.001
Major cities 204,781 (68.0) 1099 (43.7) (43.5) 178,436 (68.6) (68.2)
Inner regional 71,652 (23.8) 789 (31.4) (31.2) 60,863 (23.4) (23.7)
Outer regional 23,235 (7.7) 493 (19.6) (19.7) 19,467 (7.5) (7.6)
Remote/ Very remote 1688 (0.6) 136 (5.4) (5.7) 1309 (0.5) (0.5)
SEIFA quintile Χ2 (4) p < 0.001;
MW(z) = −23.2,
p < 0.001
1 (least disadvantaged) 62,971 (20.9) 192 (7.6) (8.1) 54,552 (21.0) (21.0)
2 54,345 (18.0) 324 (12.9) (13.0) 47,108 (18.1) (18.1)
3 61,341 (20.4) 484 (19.2) (19.4) 52,517 (20.2) (20.4)
4 68,943 (22.9) 724 (28.8) (28.3) 59,245 (22.8) (22.8)
5 (most disadvantaged) 53,756 (17.8) 793 (31.5) (31.3) 46,653 (17.9) (17.7)
Stage at diagnosis Χ2 (3) p < 0.001;
MW(z) = −9.0,
p < 0.001d
Localised 124,907 (41.5) 834 (33.1) (34.7) 102,624 (39.5) (41.5)
Regional 55,210 (18.3) 578 (23.0) (21.7) 51,572 (19.8) (18.3)
Distant 43,660 (14.5) 552 (21.9) (19.8) 42,367 (16.3) (14.4)
Unknown 77,579 (25.7) 553 (22.0) (23.8) 63,512 (24.4) (25.8)
Vital statuse Χ2 (2) p < 0.001
Alive 182,801 (60.7) 1172 (46.6) (51.9) 144,476 (55.6) (60.7)
Died due to the cancer 89,465 (29.7) 1108 (44.0) (39.6) 87,354 (33.6) (29.6)
Died due to other cause 29,090 (9.7) 237 (9.4) (8.5) 28,245 (10.9) (9.7)
Cancer site Χ2 (13) p < 0.001
Stomach 5794 (1.9) 73 (2.9) (2.7) 5544 (2.1) (1.9)
Colorectalf 40,288 (13.4) 289 (11.5) (11.0) 37,334 (14.4) (13.4)
Colon 25,794 176 (7.0) 23,832 (9.2)
Rectum 14,494 113 (4.5) 13,502 (5.2)
Liver 3433 (1.1) 50 (2.0) (1.8) 3307 (1.3) (1.1)
Pancreas 6729 (2.2) 66 (2.6) (2.3) 6539 (2.5) (2.2)
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Table 1 Characteristics of the study population overall and by Aboriginal status, NSW Cancer Registry 2000–2008 (Continued)
Lung 27,302 (9.1) 392 (15.6) (14.2) 26,161 (10.1) (9.0)
Melanoma 30,166 (10.0) 70 (2.8) (4.6) 16,966 (6.5) (10.1)
Breastg 37,266 (12.4) 331 (13.2) (13.3) 32,754 (12.6) (12.4)
Cervix 2222 (0.7) 63 (2.5) (2.6) 1908 (0.7) (0.7)
Uterus 5057 (1.7) 47 (1.9) (1.8) 4620 (1.8) (1.7)
Prostate 48,071 (16.0) 226 (9.0) (9.9) 38,712 (14.9) (16.1)
Kidney 8333 (2.8) 91 (3.6) (3.6) 7478 (2.9) (2.8)
Bladder 6912 (2.3) 43 (1.7) (1.6) 6527 (2.5) (2.3)
Ill-defined & unspecified
& other rare
11,207 (3.7) 110 (4.4) (4.1) 10,507 (4.0) (3.7)
Othersh 68,576 (22.8) 666 (26.5) (26.3) 61,718 (23.7) (22.7)
CC complete-case, MI multiple imputation, MW Mann-Whitney test, SEIFA socio-economic index for areas (Index of relative socio-economic
disadvantage was used in this study).
aIncludes also cases with unknown Aboriginal status.
bPercentage after imputing Aboriginal status.
cΧ2(df) = Pearson Chi square test (degrees of freedom) was used to test categorical differences and MW(z) = Mann-Whitney test (z value) to test
for ordinal differences between Aboriginal and non-Aboriginal people using complete-case data.
dUnknown category was excluded when Mann-Whitney test was conducted.
eVital status at end of follow-up.
fColorectal cancers grouped together and separately for colon (ICD-O-3 C18) and rectum cancers (ICD-O-3 C19-C21).
g Includes 303 cases of male breast cancer.
hAll other cancer sites categorised to this group.
Table 2 Logistic regression analysis of factors associated with advanced stage at diagnosis, NSW Cancer Registry 2000–2008
Distant Distant/regional
Unadjusted Model 1 Model 2 Unadjusted Model 1 Model 2
OR (95% CI) AOR (95% CI)a AOR (95% CI)b OR (95% CI) AOR (95% CI)a AOR (95% CI)b
Aboriginal status
Non-Aboriginal 1 1 1 1 1 1
Aboriginal 1.46 (1.33–1.61) 1.59 (1.45–1.75) 1.30 (1.17–1.44) 1.46 (1.34–1.58) 1.47 (1.36–1.60) 1.29 (1.18–1.40)
Sex
Female 1 1 1 1 1 1
Male 0.91 (0.89–0.93) 0.88 (0.86–0.90) 0.91 (0.89–0.93) 0.66 (0.65–0.67) 0.65 (0.64–0.66) 0.96 (0.94–0.98)
Residential remoteness
Major cities 1 1 1 1 1 1
Inner regional 0.94 (0.92–0.96) 0.87 (0.85–0.89) 0.91 (0.88–0.94) 0.92 (0.90–0.93) 0.89 (0.87–0.90) 0.92 (0.90–0.94)
Outer regional 1.00 (0.97–1.04) 0.90 (0.86–0.93) 0.94 (0.89–0.98) 0.96 (0.94–0.99) 0.91 (0.88–0.94) 0.95 (0.92–0.98)
Remote/ Very remote 1.19 (1.05–1.36) 1.02 (0.89–1.16) 0.97 (0.84–1.12) 1.09 (0.98–1.20) 0.98 (0.88–1.09) 0.97 (0.87–1.09)
SEIFA quintile
1 (least disadvantaged) 1 1 1 1 1 1
2 1.17 (1.13–1.21) 1.21 (1.17–1.25) 1.10 (1.06–1.14) 1.07 (1.04–1.10) 1.10 (1.07–1.12) 1.02 (0.99–1.05)
3 1.17 (1.14–1.21) 1.22 (1.18–1.26) 1.07 (1.03–1.11) 1.05 (1.03–1.08) 1.10 (1.07–1.12) 1.00 (0.97–1.03)
4 1.17 (1.13–1.21) 1.23 (1.19–1.27) 1.07 (1.03–1.11) 1.05 (1.02–1.07) 1.11 (1.08–1.13) 1.01 (0.98–1.03)
5 (most disadvantaged) 1.32 (1.28–1.36) 1.40 (1.35–1.45) 1.17 (1.13–1.22) 1.15 (1.12–1.18) 1.21 (1.18–1.24) 1.05 (1.02–1.08)
AOR adjusted odds ratio, CI confidence interval, OR odds ratio, SEIFA socio-economic index for areas (Index of relative socio-economic disadvantage was used in
this study).
aModel 1 adjusted for age, sex, year of diagnosis, remoteness and SEIFA.
bModel 2 further adjusted for cancer site.
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the association between Aboriginal status and advanced
stage of cancer are likely to reflect a complex interplay
of both individual (awareness of symptoms, reluctance
to seek treatment due to a lack of culturally appropriate
services, participating in screening) and system level
factors (access to health care services) [9]. Qualitative
research is needed to explore these reasons.
In terms of both distant and distant/regional stage, the
association between Aboriginal status and advanced
stage was detected for breast, kidney and other cancers.
The association for breast cancer may be partly ex-
plained by Aboriginal peoples participating in screening
and other early detection initiatives less frequently than
non-Aboriginal people [2, 10]. A similar association was
less clear for other cancers addressed by screening, such
as cervical cancer, although increased odds of advanced-
stage cervical cancer in Aboriginal women were found
when cases with an unknown stage/ unknown Aborigi-
nal status were excluded. Population-based screening
programs in Australia have not been able meet the needs
of priority population groups, such as Aboriginal peo-
ples, but future opportunities for improvement exist
[40]. In terms of kidney cancer, imaging tests needed for
detecting small tumours are expensive and centralised in
major specialist centres, and therefore, possibly less ac-
cessible to Aboriginal peoples.
Relative survival is the most commonly used method
to measure survival in population-based cancer studies
but a lack of detailed life tables limits the use of this
methodology for many population sub-groups [8, 41,
42]. Also life tables may not be relevant to smaller sub-
groups within these populations, such as cases with
advanced stage or those with a defined mix of socio-
demographic characteristics. Net survival (cause-spe-
cific survival and relative survival) is the probability of
surviving in the hypothetical world where the cancer
under study is the only possible cause of death (i.e., in
the absence of other causes of death). Net survival does
not provide a measure of the true probability that a pa-
tient will die of their cancer. As there is evidence that
Aboriginal peoples with cancer are more likely to die
from a non-cancer death than non-Aboriginal people
[16], it is useful to estimate the probability of cancer
death in the presence of other causes. Therefore, we
chose in this study to examine cumulative incidence of
cancer deaths by conducting competing risk regression
Table 3 Site-stratified logistic regression models of the odds of advanced stage and competing risk regression models of the hazard
of cancer death among Aboriginal compared with non-Aboriginal people, NSW Cancer Registry 2000–2008
Cancer site Distant stage Distant/regional stage Hazard of cancer death
AOR (95% CI)a AOR (95% CI)a SHR (95% CI)b
Stomach 1.01 (0.61–1.67) 0.93 (0.57–1.51) 1.23 (0.90–1.67)
Colorectalc 1.28 (0.97–1.69) 1.34 (1.05–1.70) 1.57 (1.32–1.87)
Colon 0.98 (0.68–1.42) 1.10 (0.81–1.50) 1.44 (1.13–1.84)
Rectum 1.93 (1.27–2.94) 1.82 (1.21–2.73) 1.78 (1.38–2.30)
Liver 0.66 (0.28–1.59) 0.69 (0.34–1.40) 1.27 (0.91–1.77)
Pancreas 0.83 (0.50–1.38) 0.78 (0.47–1.30) 1.16 (0.91–1.48)
Lung 0.94 (0.76–1.16) 0.95 (0.77–1.17) 1.39 (1.24–1.56)
Melanoma 1.51 (0.71–3.21) 1.61 (0.94–2.74) 1.11 (0.63–1.96)
Breastd 1.62 (1.11–2.36) 1.37 (1.10–1.71) 1.62 (1.22–2.16)
Cervixd 2.05 (0.96–4.37) 1.61 (0.94–2.74) 1.27 (0.80–2.03)
Uterusd 2.19 (1.04–4.64) 1.47 (0.80–2.70) 1.16 (0.67–2.02)
Prostated 2.59 (1.65–4.08) 1.31 (0.90–1.90) 1.86 (1.24–2.77)
Kidney 1.87 (1.16–3.03) 1.55 (1.02–2.38) 0.89 (0.59–1.35)
Bladder 0.85 (0.26–2.79) 1.40 (0.74–2.66) 0.96 (0.57–1.62)
Ill-defined & unspecified & other rare 0.99 (0.64–1.53) 0.83 (0.51–1.34) 1.26 (0.99–1.61)
Otherse 1.63 (1.30–2.04) 1.52 (1.28–1.80) 1.40 (1.23–1.59)
AOR adjusted odds ratio, CI confidence interval, SHR sub-hazard ratio, ICD-O-3 International Classification of Diseases Oncology, SEIFA socio-economic index for
areas (Index of relative socio-economic disadvantage).
aAll logistic regression models adjusted for age, sex, year of diagnosis, remoteness and SEIFA. ORs presented for Aboriginal peoples compared with
non-Aboriginal people. Separate models for distant and distant/regional as an outcome.
bAll competing risk regression models adjusted for age, sex, year of diagnosis, remoteness, SEIFA and stage. SHRs presented for Aboriginal peoples compared with
non-Aboriginal people. Death certificate only cases and cases found at post-mortem were excluded from survival analysis (1.5%) and, therefore, numbers
included in stage and survival analyses differ slightly.
cColorectal cancers grouped together and separately for colon (ICD-O-3 C18) and rectum cancers (ICD-O-3 C19-C21).
dOnly females/ males included as relevant. Only female breast cancers included in the models.
eAll other cancer sites categorised to this group.
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analyses. Competing risk regression modelling calcu-
lates the cumulative incidence of the cancer death
under study in the presence of other causes of deaths.
To our knowledge, no previous studies of survival
among Aboriginal peoples have used this method. An
advantage is that relevant population life tables are not
needed. A disadvantage is reliance on attribution of
cause of death in the NSW CR, the accuracy of which
may be uncertain. We defined the cancer cause of
death as a death matching specifically the diagnosed
cancer. Future studies should examine the impact of
using a broader definition of cancer death, e.g., as sug-
gested by the National Cancer Institute [43]. A broader
definition of cancer death would have decreased the
proportion of competing causes of deaths and conse-
quently generally decreased risk estimates. Therefore,
our approach may have underestimated the hazard of
cancer death.
Our results indicate that Aboriginal peoples have
poorer survival from cancer than non-Aboriginal people,
which is consistent with results of studies using cause-
specific survival [4, 5, 16]. Such differences are multi-
factorial and reflect differences across the spectrum of
cancer control. Aboriginal peoples were more likely to
be diagnosed with poor prognosis cancers (e.g., lung
cancer) and less likely to be diagnosed with good prog-
nosis cancers (e.g., melanoma and prostate cancer).
Nevertheless, survival disparities remained even after
Table 4 Competing risks regression models of factors associated with survival, NSW Cancer Registry 2000–2008
Unadjusted model Model 1a Model 2b Model 3c
SHR (95% CI) SHR (95% CI) SHR (95% CI) SHR (95% CI)
Aboriginal 1.47 (1.38–1.57) 1.76 (1.65–1.88) 1.54 (1.44–1.65) 1.40 (1.31–1.50)
Male 1.07 (1.05–1.08) 1.01 (0.99–1.02) 1.07 (1.05–1.08) 1.07 (1.05–1.08)
Age at diagnosis
0–39 1 1 1 1
40–49 1.52 (1.44–1.60) 1.52 (1.45–1.61) 1.39 (1.32–1.46) 1.54 (1.47–1.63)
50–59 1.97 (1.88–2.07) 2.00 (1.91–2.10) 1.78 (1.70–1.86) 1.93 (1.84–2.02)
60–64 2.26 (2.15–2.37) 2.30 (2.19–2.41) 2.01 (1.92–2.11) 2.14 (2.04–2.25)
65–69 2.54 (2.43–2.67) 2.58 (2.46–2.70) 2.25 (2.15–2.36) 2.36 (2.25–2.48)
70–74 3.23 (3.09–3.38) 3.25 (3.10–3.40) 2.73 (2.61–2.86) 2.80 (2.67–2.94)
75–79 3.79 (3.62–3.97) 3.84 (3.67–4.02) 3.19 (3.04–3.34) 3.26 (3.10–3.42)
80–84 4.59 (4.39–4.81) 4.72 (4.50–4.94) 3.89 (3.71–4.08) 4.01 (3.82–4.21)
85+ 5.78 (5.52–6.06) 5.99 (5.71–6.28) 4.84 (4.61–5.08) 5.20 (4.95–5.47)
Residential remoteness
Major cities 1 1 1 1
Inner regional 1.01 (1.00–1.03) 0.92 (0.91–0.94) 0.96 (0.94–0.98) 1.02 (1.00–1.04)
Outer regional 1.06 (1.03–1.09) 0.94 (0.92–0.97) 0.98 (0.96–1.01) 1.05 (1.02–1.08)
Remote/ Very remote 1.12 (1.03–1.22) 0.99 (0.91–1.08) 0.96 (0.87–1.05) 1.01 (0.92–1.11)
SEIFA quintile
1 (least disadvantaged) 1 1 1 1
2 1.16 (1.13–1.18) 1.19 (1.17–1.22) 1.12 (1.10–1.15) 1.09 (1.06–1.11)
3 1.22 (1.20–1.25) 1.25 (1.22–1.28) 1.18 (1.15–1.21) 1.14 (1.12–1.17)
4 1.27 (1.25–1.30) 1.29 (1.27–1.32) 1.22 (1.19–1.25) 1.17 (1.15–1.20)
5 (most disadvantaged) 1.30 (1.27–1.32) 1.38 (1.35–1.41) 1.24 (1.21–1.27) 1.15 (1.12–1.18)
Stage
Localised 1 − 1 1
Regional 2.43 (2.38–2.48) − 2.40 (2.35–2.46) 1.92 (1.88–1.96)
Distant 11.08 (10.87–11.29) − 10.32 (10.12–10.53) 5.59 (5.47–5.72)
Unknown 2.45 (2.40–2.50) − 2.15 (2.11–2.19) 1.60 (1.56–1.64)
SHR subhazard ratio, CI confidence interval, SEIFA socio-economic index for areas (Index of relative socio-economic disadvantage).
aModel 1 adjusted for age, sex, year of diagnosis, remoteness and SEIFA
bModel 2 further adjusted for stage at diagnosis.
cModel 3 further adjusted for cancer site.
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adjusting for cancer site. An elevated hazard of death
from the cancer tended to be more pronounced in Abo-
riginal peoples in the younger age groups. Similarly, a
previous study reported higher elevations in cancer mor-
tality for Aboriginal compared with non-Aboriginal
people in younger than older people [44].
An elevated hazard of death after adjustment for
demographic factors and stage was detected for colo-
rectal, lung, breast, prostate and other cancers. Previ-
ous studies utilizing cause-specific survival models
have reported similar results for a number of cancer
sites [4, 5, 7, 9, 10, 24] but also differing results for
colorectal cancer [25]. Cancer survival disparity seems
to be only partly explained by differences in stage.
Treatment-related factors, such as access to and quality
of culturally appropriate treatment, and comorbidities
are likely to play important roles [5, 16, 24]. Poorer
outcomes for Aboriginal peoples may be due to differ-
ent factors for different cancers. For example, worse
lung cancer survival among Aboriginal peoples may be
explained mostly by treatment differences and to a
lesser extent by comorbidities [7]. Any differences in
rates of treatment uptake and completion need to be
quantified carefully. Similar proportions of DCO/post-
mortem cases among Aboriginal and non-Aboriginal
people indicate that both Aboriginal and non-Aboriginal
people are responding to symptoms.
Limitations and strengths
We did not have information on individual-level factors,
such as life-style related risk factors, co-morbidities or
participation in screening, which are likely to differ be-
tween Aboriginal and non-Aboriginal peoples and have
impact on stage and survival. Socio-economic status and
remoteness were based on area-level measurements at
the time of diagnosis and may have changed during the
follow-up period. Our study included people diagnosed
in 2000–2008 and, therefore, cannot provide information
about more recent trends. The mean follow-up time was
relatively short. Strengths of the present study included
population-based data and the use of MI to address the
under-recording of Aboriginal status. After imputation,
0.94% of cases were identified as Aboriginal which is
close to the national estimate (1% of new cancer cases
being Aboriginal) [45]. Nevertheless, this is still likely to
be an underestimate due to under-recording of Aborigi-
nal status, as Aboriginal peoples account for 3% of the
Australian population [21]. Previous studies which have
used complete-case data may have underestimated the
proportion of Aboriginal peoples. In addition, deaths
due to competing events were taken into account which
is important because in general Aboriginal peoples face
higher mortality burden than non-Aboriginal people [2].
Conclusions
After accounting for competing causes of death and
more advanced stage, Aboriginal peoples had an elevated
hazard of death from cancer compared with non-
Aboriginal people. Active steps are needed to better
understand reasons for these inequalities, especially in
relation to preventable cancers, through qualitative re-
search. We consider that effects on outcomes of co-
morbidity and poorer service access and treatment
should be a main focus of future quantitative research.
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